▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2692 by analyst upside · 2026-06-27
SGRY
Surgery Partners, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+13.5%
implied upside to consensus target
Current Price $15.82
Consensus Target $17.95
Bull Target $24.0
Bear Target $14.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
3
Sell
0
52-Week Low $11.41
52-Week High $24.1
YTD Return +3.7%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 24.2x
EPS (TTM) $-0.59
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3.3B
Profit Margin -2.3%
52-WEEK RANGE
52-Week Low $11.41
52-Week High $24.1
Current Price $15.82
Bear Target $14.0
Bull Target $24.0
● Now $15.82 ● Target $17.95
TRADING DATA
Avg Volume 1.4M
YTD Return +3.7%
Analyst Count 11
Consensus Buy
Upside to Target +13.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Surgery Partners, Inc. (SGRY) is currently trading at $15.82 with a Wall Street consensus price target of $17.95, implying potential upside of 13.5% over the next 12 months. 11 analysts currently cover SGRY, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $24.0, while the most cautious has a target of $14.0.

SGRY operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 3.7% year-to-date and is currently trading near the lower end of its 52-week range of $11.41 – $24.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AVAH +16.1%
Aveanna Healthcare Holdings Inc.
$2B · P/E 7.2x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
AUPH -1.3%
Aurinia Pharmaceuticals Inc.
$2B · P/E 8.0x · Buy
SEM +0.8%
Select Medical Holdings Corporation
$2B · P/E 15.4x · Hold
MD -6.1%
Pediatrix Medical Group, Inc.
$2B · P/E 12.0x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for SGRY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen — Reiterated
Buy → Buy 2026-03-05 Building track record
UBS — Reiterated
Buy → Buy 2026-03-05 33% win rate (6 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-03-05 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-03-04 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-03-03 Building track record
Mizuho — Reiterated
Outperform → Outperform 2025-12-18 Building track record
JP Morgan — Reiterated
Neutral → Neutral 2025-11-24 43% win rate (7 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2025-11-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
19/30
Consensus clarity
17/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →